Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Off the scrapheap of discarded drugs and on its way to becoming the most highly anticipated approval of 2024, Bristol Myers Squibb’s schizophrenia treatment Cobenfy (KarXT) has had an unusual ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

With many of the Magnificent 7 stocks reporting earnings the week of October 28, investors’ attention was on technology ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bristol-Myers Squibb (BMY – Research Report) and Envista ...

David Risinger, an analyst from Leerink Partners, maintained the Hold rating on Bristol-Myers Squibb (BMY – Research Report). The associated price target was raised to $55.00. David Risinger has given ...

The U.S. drugmaker is turning to deals at a time when two of its top drugs, blood cancer treatment Revlimid and blood thinner Eliquis, face generic competition. Karuna’s crown jewel, an ...

Bristol Myers Squibb offers a strong dividend yield, below-average valuation, and solid growth prospects, making it a compelling buy. BMY's robust pipeline, including advancements in ...

Based in New York, New York, Bristol-Myers Squibb Company (BMY) is a global biopharmaceutical leader focused on discovering, developing, and delivering innovative medicines. With a market cap of $ ...

Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...